Drugs / EB-DT-CAR-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07551362 | Mar 2026 → Mar 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DT-CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07551362 ↗ |
| Modality | Cell therapy | “Allogeneic, cord-blood-derived CAR-NK cells engineered to target CLDN18.2 and HER2 (ERBB2).” NCT07551362 ↗ |
| Target | CLDN18 | “engineered to target CLDN18.2” NCT07551362 ↗ |
| Target | ERBB2 | “engineered to target CLDN18.2 and HER2 (ERBB2)” NCT07551362 ↗ |